The European RBDCOV project will study HIPRA’s COVID-19 vaccine in children, adolescents and immunocompromised patients

Back to the "Press releases and Statements" list

January 20th 2022


Funded by the Horizon Europe programme, RBDCOV will test the efficacy, tolerability, and safety of the vaccine against the different variants of COVID-19 using a recombinant protein.


RBD Dimer recombinant protein vaccine against SARSCoV2” (RBDCOV) is a new Horizon Europe project led by the biotech pharmaceutical company HIPRA. Launched on 1st December, RBDCOV project objective is to test the efficacy, tolerability, and safety of the HIPRA’s recombinant Covid-19 vaccine in children (including adolescents) and immunocompromised people. The trials will last 2.5 years.


To carry out this project, HIPRA will work with an international consortium including companies and institutions from five European countries: Spain (IRSICAIXA, FUNDACIO HOSPITAL UNIVERSITARI VALL D’HEBRON, FUNDACION FILS DE LUCHA CONTRA ELSIDA (FLS), IDIBAPS, IDIBGI, ASPHALION, VINCES CONSULTING, ZABALA INNOVATION), United Kingdom (VERISTAT INTERNATIONAL), Italy (FONDAZIONE PENTA), Germany  (EUROPEAN AIDS TREATMENT GROUP), and Turkey (METPHARM ARASTIRMA GELISTIRME SAGLIK DANISMANLIK). The project will manage a budget of EUR 9.779.211,25 euros.


Prolonging the protection of immunocompromised persons


The RBDCOV project foresees two clinical trials, one in a group of immunocompromised individuals and the second study in one or more groups of children and adolescents. The RBDCOV project will contribute to the development of the HIPRA vaccine which aims to protect against severe COVID infection including in immunocompromised individuals and to ensure a long-term immune response.


The Project also envisages that the vaccine will be made accessible for vaccination campaigns worldwide thanks to its 2-8º C storage temperature, which facilitates a longer lasting shelf-life, transport, and distribution.


HIPRA’s vaccine


The COVID-19 vaccine being developed by HIPRA is a recombinant adjuvanted protein vaccine based on a Receptor Binding Domain (RBD) fusion heterodimer containing the B.1.1.7 (alpha) and B.1.351 (beta) variants of SARS-CoV-2.



RBDCOV and the impulse for innovation against COVID-19 in Europe


The Horizon Europe Framework Programme is Europe’s largest research and innovation programme (2021-2027), and one of its priorities is to support urgent research on coronavirus and its variants. The European Commission has selected eleven projects involving 312 research teams from 40 countries. RBDCOV is one of the selected projects that will support clinical trials for a new vaccine that can reach beyond Europe’s borders by creating links with other European initiatives.


Mariya Gabriel, European Commissioner for Innovation and Research, announced last year the approval of the RBDCOV project along with other 10 initiatives, stressing that investment in innovation is key to tackling the coronavirus crisis and strengthening current research infrastructures for the pandemic and future emergencies.


More information:

Press Officer:

Susana Garayoa

Phone number: M (+32) 484 61 91 64



Amaia Cabezón

Phone number: M (+34) 673 744 542



The RBDCOV project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101046118

Source : RBDCOV

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?


Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.